http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 27 May 2026 16:33:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+May+22++Filed+by%3A+Weis+Holger/26558474.html si-local-file:///var/storage/secattach/20260527/26558474.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+May+22++Filed+by%3A+Weis+Holger/26558474.html Wed, 27 May 2026 16:33:00 -0400 O.01405601 TCRT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+May+22++Filed+by%3A+Weis+Holger/26558474.html si-local-file:///var/storage/secattach/20260527/26558474.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Alaunos+Therapeutics%2C+++++For%3A+May+22++Filed+by%3A+Weis+Holger/26558474.html Wed, 27 May 2026 16:33:00 -0400 O.01405601 TCRT http://www.streetinsider.com/Corporate+News/Alaunos+reports+obesity+drug+shows+weight+loss+in+mouse+studies/26547735.html <p>Alaunos Therapeutics Inc. (NASDAQ: TCRT) reported that its experimental obesity drug ALN1003 demonstrated weight reduction and metabolic improvements in two mouse studies.</p><p>The Fort Lauderdale-based company said ALN1003 showed body weight reductions of up to 12.9% in a 48-day study and up to 30.5% in an 18-day dose-ranging study using diet-induced obese mice. The drug also reduced fat mass while maintaining lean muscle mass as a percentage of body weight.</p><p>In the longer study, mice treated with ALN1003 showed lower fasting insulin levels and improved insulin sensitivity markers. The treatment was associated with higher adiponectin levels and lower liver weight, along with http://www.streetinsider.com/Corporate+News/Alaunos+reports+obesity+drug+shows+weight+loss+in+mouse+studies/26547735.html Tue, 26 May 2026 11:02:44 -0400 TCRT http://www.streetinsider.com/FDA/Alaunos+reports+obesity+drug+shows+weight+loss+in+mouse+studies/26547735.html <p>Alaunos Therapeutics Inc. (NASDAQ: TCRT) reported that its experimental obesity drug ALN1003 demonstrated weight reduction and metabolic improvements in two mouse studies.</p><p>The Fort Lauderdale-based company said ALN1003 showed body weight reductions of up to 12.9% in a 48-day study and up to 30.5% in an 18-day dose-ranging study using diet-induced obese mice. The drug also reduced fat mass while maintaining lean muscle mass as a percentage of body weight.</p><p>In the longer study, mice treated with ALN1003 showed lower fasting insulin levels and improved insulin sensitivity markers. The treatment was associated with higher adiponectin levels and lower liver weight, along with http://www.streetinsider.com/FDA/Alaunos+reports+obesity+drug+shows+weight+loss+in+mouse+studies/26547735.html Tue, 26 May 2026 11:02:44 -0400 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>A non-confidential investor presentation summarizing the preclinical dataset is now available</em></li></ul> <p align="justify">FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today reported an integrated preclinical readout for ALN1003, the Company&apos;s investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The readout consolidates findings from two non-Good Laboratory Practice (non-GLP) diet-induced obesity http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html Tue, 26 May 2026 11:01:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>A non-confidential investor presentation summarizing the preclinical dataset is now available</em></li></ul> <p align="justify">FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today reported an integrated preclinical readout for ALN1003, the Company&apos;s investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The readout consolidates findings from two non-Good Laboratory Practice (non-GLP) diet-induced obesity http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html Tue, 26 May 2026 11:01:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>A non-confidential investor presentation summarizing the preclinical dataset is now available</em></li></ul> <p align="justify">FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today reported an integrated preclinical readout for ALN1003, the Company&apos;s investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The readout consolidates findings from two non-Good Laboratory Practice (non-GLP) diet-induced obesity http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html Tue, 26 May 2026 11:01:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>A non-confidential investor presentation summarizing the preclinical dataset is now available</em></li></ul> <p align="justify">FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today reported an integrated preclinical readout for ALN1003, the Company&apos;s investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The readout consolidates findings from two non-Good Laboratory Practice (non-GLP) diet-induced obesity http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html Tue, 26 May 2026 11:01:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>A non-confidential investor presentation summarizing the preclinical dataset is now available</em></li></ul> <p align="justify">FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today reported an integrated preclinical readout for ALN1003, the Company&apos;s investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The readout consolidates findings from two non-Good Laboratory Practice (non-GLP) diet-induced obesity http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html Tue, 26 May 2026 11:01:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>A non-confidential investor presentation summarizing the preclinical dataset is now available</em></li></ul> <p align="justify">FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today reported an integrated preclinical readout for ALN1003, the Company&apos;s investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The readout consolidates findings from two non-Good Laboratory Practice (non-GLP) diet-induced obesity http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html Tue, 26 May 2026 11:01:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>A non-confidential investor presentation summarizing the preclinical dataset is now available</em></li></ul> <p align="justify">FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today reported an integrated preclinical readout for ALN1003, the Company&apos;s investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The readout consolidates findings from two non-Good Laboratory Practice (non-GLP) diet-induced obesity http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html Tue, 26 May 2026 11:01:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>A non-confidential investor presentation summarizing the preclinical dataset is now available</em></li></ul> <p align="justify">FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today reported an integrated preclinical readout for ALN1003, the Company&apos;s investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The readout consolidates findings from two non-Good Laboratory Practice (non-GLP) diet-induced obesity http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Broad+Metabolic+Improvements+with+ALN1003+in+Obese+Mouse+Studies/26547724.html Tue, 26 May 2026 11:01:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alaunos+Therapeutics%2C+++++For%3A+May+26/26547727.html si-local-file:///var/storage/secattach/20260526/26547727.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alaunos+Therapeutics%2C+++++For%3A+May+26/26547727.html Tue, 26 May 2026 11:01:00 -0400 O.01405601 TCRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alaunos+Therapeutics%2C+++++For%3A+May+26/26547727.html si-local-file:///var/storage/secattach/20260526/26547727.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alaunos+Therapeutics%2C+++++For%3A+May+26/26547727.html Tue, 26 May 2026 11:01:00 -0400 O.01405601 TCRT http://www.streetinsider.com/Corporate+News/Alaunos+reports+preclinical+data+for+metabolic+drug+candidate+ALN1003/26510553.html <p>Alaunos Therapeutics Inc. (NASDAQ: TCRT) announced preclinical data from diet-induced obesity mouse studies for its oral metabolic therapeutic candidate ALN1003. The company reported effects on insulin-resistance-related biomarkers and liver histology in the studies.</p><p>In a 48-day study, ALN1003 was associated with significantly lower fasting insulin and lower Homeostasis Model Assessment of Insulin Resistance scores compared to controls after adjustment for body fat percentage. The treatment group showed significantly lower HOMA-IR scores with a p-value of 0.0006 in standard analysis and 0.0014 in sensitivity analysis.</p><p>The compound was also associated with numerically lower leptin levels, significantly higher adiponectin, and a significantly higher adiponectin-to-leptin http://www.streetinsider.com/Corporate+News/Alaunos+reports+preclinical+data+for+metabolic+drug+candidate+ALN1003/26510553.html Mon, 18 May 2026 08:02:44 -0400 TCRT http://www.streetinsider.com/FDA/Alaunos+reports+preclinical+data+for+metabolic+drug+candidate+ALN1003/26510553.html <p>Alaunos Therapeutics Inc. (NASDAQ: TCRT) announced preclinical data from diet-induced obesity mouse studies for its oral metabolic therapeutic candidate ALN1003. The company reported effects on insulin-resistance-related biomarkers and liver histology in the studies.</p><p>In a 48-day study, ALN1003 was associated with significantly lower fasting insulin and lower Homeostasis Model Assessment of Insulin Resistance scores compared to controls after adjustment for body fat percentage. The treatment group showed significantly lower HOMA-IR scores with a p-value of 0.0006 in standard analysis and 0.0014 in sensitivity analysis.</p><p>The compound was also associated with numerically lower leptin levels, significantly higher adiponectin, and a significantly higher adiponectin-to-leptin http://www.streetinsider.com/FDA/Alaunos+reports+preclinical+data+for+metabolic+drug+candidate+ALN1003/26510553.html Mon, 18 May 2026 08:02:44 -0400 TCRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alaunos+Therapeutics%2C+++++For%3A+May+18/26510504.html si-local-file:///var/storage/secattach/20260518/26510504.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alaunos+Therapeutics%2C+++++For%3A+May+18/26510504.html Mon, 18 May 2026 08:01:00 -0400 O.01405601 TCRT http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alaunos+Therapeutics%2C+++++For%3A+May+18/26510504.html si-local-file:///var/storage/secattach/20260518/26510504.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Alaunos+Therapeutics%2C+++++For%3A+May+18/26510504.html Mon, 18 May 2026 08:01:00 -0400 O.01405601 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html <p align="justify">FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT) </strong>today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company&apos;s investigational oral metabolic therapeutic candidate. Across selected biomarker and liver histology assessments, ALN1003 showed effects on insulin-resistance-related measures, adipose endocrine markers, and qualitative liver pathology findings relevant to metabolic syndrome biology. These findings support continued preclinical development of ALN1003 in metabolic syndrome and related conditions, including obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and insulin resistance.</p> <p align="justify">Metabolic syndrome is increasingly understood not as a collection of http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html <p align="justify">FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT) </strong>today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company&apos;s investigational oral metabolic therapeutic candidate. Across selected biomarker and liver histology assessments, ALN1003 showed effects on insulin-resistance-related measures, adipose endocrine markers, and qualitative liver pathology findings relevant to metabolic syndrome biology. These findings support continued preclinical development of ALN1003 in metabolic syndrome and related conditions, including obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and insulin resistance.</p> <p align="justify">Metabolic syndrome is increasingly understood not as a collection of http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html <p align="justify">FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT) </strong>today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company&apos;s investigational oral metabolic therapeutic candidate. Across selected biomarker and liver histology assessments, ALN1003 showed effects on insulin-resistance-related measures, adipose endocrine markers, and qualitative liver pathology findings relevant to metabolic syndrome biology. These findings support continued preclinical development of ALN1003 in metabolic syndrome and related conditions, including obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and insulin resistance.</p> <p align="justify">Metabolic syndrome is increasingly understood not as a collection of http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html <p align="justify">FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT) </strong>today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company&apos;s investigational oral metabolic therapeutic candidate. Across selected biomarker and liver histology assessments, ALN1003 showed effects on insulin-resistance-related measures, adipose endocrine markers, and qualitative liver pathology findings relevant to metabolic syndrome biology. These findings support continued preclinical development of ALN1003 in metabolic syndrome and related conditions, including obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and insulin resistance.</p> <p align="justify">Metabolic syndrome is increasingly understood not as a collection of http://www.streetinsider.com/Press+Releases/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html <p align="justify">FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT) </strong>today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company&apos;s investigational oral metabolic therapeutic candidate. Across selected biomarker and liver histology assessments, ALN1003 showed effects on insulin-resistance-related measures, adipose endocrine markers, and qualitative liver pathology findings relevant to metabolic syndrome biology. These findings support continued preclinical development of ALN1003 in metabolic syndrome and related conditions, including obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and insulin resistance.</p> <p align="justify">Metabolic syndrome is increasingly understood not as a collection of http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html <p align="justify">FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT) </strong>today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company&apos;s investigational oral metabolic therapeutic candidate. Across selected biomarker and liver histology assessments, ALN1003 showed effects on insulin-resistance-related measures, adipose endocrine markers, and qualitative liver pathology findings relevant to metabolic syndrome biology. These findings support continued preclinical development of ALN1003 in metabolic syndrome and related conditions, including obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and insulin resistance.</p> <p align="justify">Metabolic syndrome is increasingly understood not as a collection of http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 O.01405601 O.20026344 TCRT http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html <p align="justify">FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- <strong>Alaunos Therapeutics, Inc. (Nasdaq: TCRT) </strong>today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company&apos;s investigational oral metabolic therapeutic candidate. Across selected biomarker and liver histology assessments, ALN1003 showed effects on insulin-resistance-related measures, adipose endocrine markers, and qualitative liver pathology findings relevant to metabolic syndrome biology. These findings support continued preclinical development of ALN1003 in metabolic syndrome and related conditions, including obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and insulin resistance.</p> <p align="justify">Metabolic syndrome is increasingly understood not as a collection of http://www.streetinsider.com/Globe+Newswire/Alaunos+Reports+Preclinical+ALN1003+Data+Showing+Effects+on+Insulin-Resistance-Related+Biomarkers+and+Liver+Histology+in+Diet-Induced+Obesity+Models/26510463.html Mon, 18 May 2026 08:00:00 -0400 A.06822034 O.01405601 O.20026344 TCRT